Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein cytoplasmic 1 light intermediate chain 2 (DYNC1LI2)
- Target
- DYNC1LI2
- Molecular classification
- Motor protein complex subunit, Cytoplasmic dynein complex accessory protein, Other
01
Overview
Dynein cytoplasmic 1 light intermediate chain 2 (DYNC1LI2) is a non-catalytic accessory subunit of the cytoplasmic dynein 1 motor protein complex which is essential for retrograde transport of vesicles and organelles along microtubules. DYNC1LI2 binds to dynein cargos and adaptor proteins, determining cargo specificity and regulating membrane trafficking events, lysosome and endosome positioning, and Golgi integrity. It plays a critical role in mitosis—especially spindle orientation and checkpoint control. Downregulation or mutation of DYNC1LI2 impairs vesicular trafficking and contributes to diseases such as cystinosis and certain ciliopathies. Post-translational modifications, such as arginine methylation, regulate its interaction with adaptors and diverse cargo, enabling the dynein complex to fulfill various specialized roles in the cell. Currently, it is not considered a direct therapeutic target and has no known drug interactions.
- Other names
- DNCLI2LIC2LIC-2Dynein light intermediate chain 2, cytosolicLIC53/55cytoplasmic dynein 1 light intermediate chain 2dynein cytoplasmic 1 light intermediate polypeptide 2DC1L2
02
Biological functions
Intracellular retrograde transport along microtubulesMembrane trafficking and vesicle/organelle motilityRecruitment of dynein to late endocytic membranesRegulation of mitotic spindle orientationSpindle assembly checkpoint inactivationPositioning of lysosomes, late endosomes, Golgi apparatusModulation of microtubule organization and cell migrationRegulation of chaperone-mediated autophagy via LAMP2A trafficking
03
Disease associations
Lysosomal storage disorders (e.g., cystinosis)Bardet-Biedl syndromeOsteosarcoma (biological association, not therapeutic targeting)Other
04
Safety considerations
No direct safety concerns described for therapeutic targeting; not a known drug target
Beyond the preview
Go deeper on Dynein cytoplasmic 1 light intermediate chain 2 (DYNC1LI2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dynein cytoplasmic 1 light intermediate chain 2 (DYNC1LI2).